Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc. (DVA) director Jason M. Hollar reported an acquisition of company stock through an equity grant. On 2026-08-15, he received 278 shares of DaVita common stock at a reported price of $0.00 per share, increasing his directly held position to 6,883 shares of common stock after the transaction.
DAVITA INC. (symbol: DVA) is the issuer of record for a Form 4 filing submitted to the SEC.
DaVita Inc. (DVA) director Adam H. Schechter reported an automatic equity acquisition. He received a grant of 278 shares of Common Stock on August 15, 2026, recorded at a price of $0.00 per share as an award, bringing his direct holdings to 5,970 shares after the transaction.
DAVITA INC. (DVA) reported that a board director received an equity grant of common stock. Reporting person Gregory J. Moore was awarded 278 shares of DaVita common stock on August 15, 2026, at a stated price of $0.00 per share, increasing his directly held position to 8,091 shares after the transaction. The filing indicates this award was a grant, award, or other acquisition of stock and that it was not executed under a Rule 10b5-1 trading plan.
DaVita Inc. (DVA) reported an insider equity award to board member Dennis W. Pullin. On 2026-08-15, Pullin received a grant of 278 shares of Common Stock at a stated price of $0.00 per share, classified as a grant, award, or other acquisition. Following this award, his directly held Common Stock position increased to 2,949 shares.
DAVITA INC. (symbol: DVA) is the issuer of record for a Form 4 filing submitted to the SEC.
DAVITA INC. (symbol: DVA) is the issuer of record for a Form 4 filing submitted to the SEC.
DaVita Inc. (DVA) reported an insider equity award to board member Phyllis R. Yale. On 2026-08-15 she received a grant of 278 shares of Common Stock at a stated price of $0.00 per share, classified as a grant/award acquisition. Following this award, she directly holds 9,803 DaVita common shares. No sales or derivative transactions were reported in this filing.
Berkshire Hathaway Inc. and Warren E. Buffett, as 10% owners of DaVita Inc., reported an indirect sale of 182,980 shares of common stock on July 31, 2026 at $199.548 per share. After this sale, entities associated with Berkshire held 28,697,229 shares indirectly, primarily through Government Employees Insurance Company and certain pension plans, while Berkshire and Mr. Buffett disclaim beneficial ownership beyond any pecuniary interest.